Amphastar Pharmaceuticals AMPH Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligations.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's long-term debt?
- Amphastar Pharmaceuticals (AMPH) reported long-term debt of $609.8M in Q1 2026.
- How has Amphastar Pharmaceuticals's long-term debt changed year-over-year?
- Amphastar Pharmaceuticals's long-term debt increased by 1.0% year-over-year, from $603.86M to $609.8M.
- What is the long-term trend for Amphastar Pharmaceuticals's long-term debt?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's long-term debt has grown at a 77.9% compound annual growth rate (CAGR), from $34.19M to $608.75M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.